# Agenus Inc.: Phase 2 study closed enrollment, 234 enrolled (Metastatic Colorectal Cancer)

**Score:** 100/100

| Field | Value |
|---|---|
| Sponsor | Agenus Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer |
| NCT ID | NCT05608044 |
| Phase | Phase 2 |
| Status | active not recruiting |
| Conditions | Metastatic Colorectal Cancer |
| Intervention types | drug |
| Target enrollment | 234 |
| Site countries | United States, Belgium, Brazil, France, Georgia, Italy, Russia, Spain |
| Posted | 2022-11-08 |
| Planned start | 2022-11-30 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-11-05 |
| Last update posted | 2026-11-05 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 2: multi-site, larger budget.
- 234 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05608044). Last refreshed: 2026-11-06T09:49:51.899Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.